About Us

A Differentiated Approach to Target and Drug Discovery

Who We Are

We are a pioneering clinical-stage biotechnology company committed to the development of innovative therapeutics for immune-mediated inflammatory diseases (IMIDs) using the power of artificial intelligence (AI) and machine learning (ML). Our focus lies in identifying novel targets and drugs by decoding the intricate mechanisms and pathways that drive the initiation and progression of inflammation in patients with debilitating IMIDs such as atopic dermatitis (AD), indolent systemic mastocytosis (ISM), and eosinophilic esophagitis (EoE).

Our Vision

Addressing Unmet Medical Needs​

IMIDs represent a diverse group of conditions characterized by common inflammatory pathways, and they present an urgent need for safe, efficacious, and long-term oral therapies. Through our innovative strategy, we integrate AI and ML analyses with the expertise of domain specialists to identify targets, understand their association with symptomatology across the IMIDs spectrum, and uncover potential therapeutics that can effectively impact chronic inflammation. 

Our Future Endeavors

We recognize the substantial burden imposed by dermatologic and gastrointestinal disorders on patients’ lives, healthcare systems, and the economy. While conventional therapies like corticosteroids are commonly used, their limitations and associated adverse events call for more selective and effective treatments. Our goal is to develop novel oral small molecule therapies that precisely target inflammation, addressing the root cause of IMIDs and promoting improved outcomes for patients. 

We were spun out by InveniAI, our parent, in 2021 and are headquartered in Guilford, Connecticut.

Meet our team

We leverage an executive team and board of directors and advisors with a track record of creating lasting impact in healthcare innovation.